LONDON - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a company specializing in artificial intelligence-enabled in vitro diagnostics for kidney disease, reported recent transactions by its directors and persons discharging managerial responsibilities (PDMRs). These transactions involved both the sale and purchase of the company's ordinary shares.
On Monday, Christopher Mills, the Non-Executive Chairman, sold 48,601 ordinary shares at £0.07 each through certain investment vehicles connected to him. Post-sale, Mills and his associated investment vehicles hold 14,561,345 ordinary shares, which equates to a 4.4% stake in Renalytix.
James McCullough, the CEO, purchased 25,000 ordinary shares on Tuesday at £0.085 per share. Following this acquisition, McCullough's interest in the company amounts to 3,242,096 ordinary shares or 0.98% of the issued share capital.
Additionally, Howard Doran, President of Renalytix, bought 50,000 ordinary shares at £0.089 per share. Doran now holds 100,000 shares, representing a 0.03% interest in the company.
Julian Baines, the Executive Chairman, also participated in the buying, acquiring 23,000 ordinary shares at £0.085 each. Baines's stake in the company has increased to 1,848,700 ordinary shares, or 0.56% of the issued share capital.
These transactions are part of the regular financial activities of company executives and are reported in compliance with market regulations. Share dealings by company insiders are closely monitored as they can provide insights into the leadership's confidence in the company's prospects.
This information is based on a press release statement and provides a factual account of the recent share dealings by Renalytix executives. It is important for investors to consider such transactions in their broader market analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.